Announcement on Voluntary Disclosure of the Completion of Full Subject Enrollment in the Phase III Clinical Trial of D-2570 for Psoriasis

About this update from Inventisbio, Co., Ltd. Class A

Announcement on Voluntary Disclosure of the Completion of Full Subject Enrollment in the Phase III Clinical Trial of D-2570 for Psoriasis The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Inventisbio, Co., Ltd. Class A